Eupraxia Pharmaceuticals Inc News

Eupraxia Pharmaceuticals Up 5.5% In US Premarket As Says DiffuSphere Technology Demonstrates Targeted Drug Release

MT NewswiresNov 20 08:11 ET

Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release While Minimizing Systemic Exposure for a Period of More Than Six Months

PR NewswireNov 20 07:00 ET

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

PR NewswireNov 14 17:00 ET

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

PR NewswireNov 13 17:00 ET

Express News | Eupraxia Pharmaceuticals Inc : Raymond James Cuts Target Price to $12 From $16.50

ReutersNov 13 07:40 ET

MT Newswires Stocks To Watch: Eupraxia Pharmaceuticals and I-80 Gold. Also Conifex, Crown; Dream Unlimited; DCM; NGEx; Peyto; Primaris REIT; VIQ Solutions

MT NewswiresNov 12 20:37 ET

Eupraxia Pharmaceuticals Inc: INTERIM MDA EN

SEDARNov 7 17:07 ET · Announcements

Eupraxia Pharmaceuticals Inc: INTERIM FINANCIAL STATEMENTSREPORT EN

SEDARNov 7 17:06 ET · Announcements

Press Release: Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Dow JonesNov 7 17:00 ET

MT Newswires Canada Stocks To Watch: Cogecos; Black Diamond; Brookfield Asset Management and Brookfield Corp; Eupraxia

MT NewswiresOct 31 20:31 ET

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR

MT NewswiresOct 15 07:31 ET

Eupraxia Pharmaceuticals Details Executive Appointments

MT NewswiresOct 2 17:25 ET

Eupraxia Pharmaceuticals Brief: Appointing Chief Scientific Officer Amanda Malone, as Chief Operating and Scientific Officer, and Rahul Sarugaser, as Executive Vice President of Corporate Development

MT NewswiresOct 2 17:02 ET

Eupraxia Pharmaceuticals Reports Positive Data From RESOLVE Trial

MT NewswiresSep 11 08:15 ET

Eupraxia's EP-104GI Shows Promise in EoE Trial

TipRanksSep 11 07:27 ET

Eupraxia Pharmaceuticals Brief: Announcing Data From RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

MT NewswiresSep 11 07:02 ET

Eupraxia Pharmaceuticals Announces Data From RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

PR NewswireSep 11 07:00 ET

Press Release: Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Dow JonesAug 7 17:00 ET

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

PR NewswireJul 8 07:00 ET

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

PR NewswireJul 3 17:00 ET